Previous close | 164.00 |
Open | 163.84 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's range | 162.05 - 164.74 |
52-week range | 132.24 - 243.52 |
Volume | |
Avg. volume | 1,509,484 |
Market cap | 24.048B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 26.58 |
EPS (TTM) | 6.15 |
Earnings date | 24 Jan 2024 - 29 Jan 2024 |
Forward dividend & yield | 1.92 (1.17%) |
Ex-dividend date | 08 Nov 2023 |
1y target est | 178.38 |
Published in the Journal of the American Medical Association Network Open, study estimates global COPD burden from 2020 through 2050 Study projects disproportionate growth in COPD among women and low-middle income regions SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the results of a study on the global burden of Chronic Obstructive Pulmonary Disease (COPD) through 2050. Published in the Journal of the American Medical Association (JAMA) Network Open,
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.